{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-056198","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.134173+00:00","generated_at":"2026-06-28T10:07:49.109436+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nkarta reports Q3 net loss of $22.4M; NKX101 data pushed to 1H 2022","bullets":["Net loss of $22.4M ($0.68 per share); R&D expense $16.6M, G&A $5.8M.","Cash, equivalents, restricted cash and short-term investments totaled $259.8M; runway into at least 2H 2023.","NKX101 Phase 1 data for AML/MDS expected in 1H 2022 (updated from prior guidance).","First patients dosed in NKX019 Phase 1 for B cell malignancies; initial data expected in 2022.","Leased new 88,000 sq ft manufacturing facility and HQ to support pivotal trials and commercial launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-056198","json":"https://secwatch.observer/filing/0001564590-21-056198.json","markdown":"https://secwatch.observer/filing/0001564590-21-056198.md","text":"https://secwatch.observer/filing/0001564590-21-056198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000156459021056198/0001564590-21-056198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000156459021056198/nktx-8k_20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:07:49.109436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}